Ybrain

Ybrain is a company that has developed a range of non-invasive electroceutical devices and platforms for the treatment of various neuropsychiatric disorders and mental health management. Their key products include transcranial direct current stimulation (tDCS) technology for improving cognitive ability and treating conditions like depression, attention deficit hyperactivity disorder (ADHD), and mild cognitive impairment. Ybrain successfully conducted the world's first at-home clinical trial of their tDCS platform for treating major depressive disorder and obtained approval from South Korean authorities for its marketing.

The company has also developed high-definition tDCS (HD-tDCS) technology with 16 channels, enabling precise targeting and focused stimulation of specific brain regions. This technology is currently undergoing clinical trials for conditions like Parkinson's disease and stroke, which require precise stimulation. Additionally, Ybrain has commercialized a nerve stimulation device for migraine relief and prevention, utilizing a patented stimulation technology that combines pulse, burst, and DC stimulation.

Ybrain's product offerings extend to electroencephalogram (EEG) devices for brain activity monitoring, diagnosis, and treatment of neurological diseases and brain injuries. Their MINDD SCAN, a 19-channel EEG device with neurofeedback capabilities, is widely used in medical research and clinical trials. The company also provides heart rate variability (HRV) analysis solutions for evaluating cardiovascular health and autonomic nervous system function.

Furthermore, Ybrain has developed mental health platforms and solutions, including self-assessment tools based on clinical data and AI-based analysis of bio-signals like EEG and HRV. These platforms offer integrated mental health management solutions using electroceuticals or digital treatment technologies. As of July 2023, around 80 hospitals and clinics in South Korea were using Ybrain's tDCS technology for improving depressive symptoms.